VANCOUVER and SAN DIEGO, May 25 /PRNewswire-FirstCall/ -- MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a developer of drugs for infectious and degenerative diseases, has issued its 18th CEO Message from Jim DeMesa, MD, President & CEO. Today's CEO Message provided an overview of the Company's value-driving milestones over the next year and beyond:
- MX-3253 Phase II hepatitis c virus (HCV) non-responder study results
(October 2006)
- MX-3253 Phase II HCV viral kinetics study results in treatment-naive
patients (late 2006/early 2007)
- CPI-226 Phase III results for preventing catheter-related infections
(first half 2007) and an NDA submission to follow (with positive Phase
III results)
- Partnering opportunities with MX-3253 (option arrangement with
Schering-Plough) and MX-226 for Japan and ROW where MIGENIX holds the
rights (also called CPI-226 in North America and Europe through our
license agreement with Cadence Pharmaceuticals)
To obtain a copy of the complete CEO Message, please visit the MIGENIX web site at http://www.migenix.com/ or contact Investor Relations at 1-800-665-1968, Extension 233.
About MIGENIX
MIGENIX is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C infections (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I) and the treatment of acne (Phase II). MIGENIX is headquartered in Vancouver, British Columbia, Canada with US operations in San Diego, California. Additional information can be found at http://www.migenix.com/.
"Jim DeMesa"
James M. DeMesa, M.D.
President & CEO
Forward-Looking Statements
Certain statements in this news release contain forward-looking statements or information under applicable Canadian and United States securities legislation. All statements or information other than statements of historical fact may be deemed to be forward-looking statements or information. Forward-looking statements frequently, but not always, use the words "intends", "plans", "believes", "anticipates" or "expects" or similar words; that events "will", "may", "could" or "should" occur; and/or include statements or information concerning our strategies, goals, plans and expectations. Forward-looking statements or information in this news release include, but are not limited to statements or information concerning: the Company's milestones over the next year and beyond driving value significantly (milestones are: two MX-3253 Phase II hepatitis C virus (HCV) study results; CPI-226 Phase III results and an NDA submission to follow; and partnering opportunities with MX-3253 and MX-226). We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements or information and you should not place undue reliance on our forward-looking statements or information. Factors that could cause actual events or results expressed or implied by such forward looking statements to differ materially from any future results expressed or implied by such statements or information include, but are not limited to: uncertainties related to early stage of technology and product development; dependence on corporate collaborations; uncertainties as to future expense levels and the possibility of unanticipated costs or expenses or cost overruns, the possibility that opportunities will arise that require more cash than presently anticipated and other uncertainties related to predictions of future cash requirements; uncertainties as to the requirement that a drug be found to be safe and effective after extensive clinical trials and the possibility that the results of such trials, if commenced and completed, will not establish the safety or efficacy of our products; risks relating to requirements for approvals by government agencies such as the FDA and/or Health Canada before products can be tested in clinical trials and ultimately marketed; the possibility that such government agency approvals will not be obtained in a timely manner or at all or will be conditioned in a manner that would impair our ability to advance development and/or market the product successfully; management of growth; dependence on key personnel; the possibility that we will not successfully develop any products; the possibility that advances by competitors will cause our proposed products not to be viable, the risk that our patents could be invalidated or narrowed in scope by judicial actions or that our technology could infringe the patent or other intellectual property rights of third parties; the possibility that any products successfully developed by us will not achieve market acceptance; and other risks and uncertainties which may not be described herein. Certain of these factors and other factors are described in detail in the Company's Annual Information Form and Annual Report on Form 20-F and other filings with the Canadian securities regulatory authorities and the U.S. Securities & Exchange Commission. Forward-looking statements are based on our current expectations and MIGENIX assumes no obligations to update such information to reflect later events or developments.
The Toronto Stock Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release.
MIGENIX Inc.
BC Research Complex
3650 Wesbrook Mall
Vancouver, BC V6S 2L2
Canada
